Created On: 2020-07-15
Record Count: 4
- Drug Discovery
- Central Nervous System
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 274908
In order to establish co-exclusivity, Licensor shall not grant, during the Term, more than three other co-exclusive licenses to the MPG Patent Rights in the Field with the scope as set forth (hereinafter the â€œOther Diagnostic Licensesâ€, or the 'Other Diagnostic Licensees', as applicable).
Licensed Products shall mean any product (I) that, or the development, manufacture, use or sale of which, absent the license granted hereunder, would infringe one or more Pending Claims or Valid Claims of the MPG Patent Rights, or (ii) which is developed or manufactured by using a Licensed Process or that, when used, practices a Licensed Process.
MPG Patent Rights shall mean: (Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V. (hereinafter â€œMPGâ€œ), a German non-profit scientific research organisation)
the patent applications filed by MPG listed, and the resulting patents,
any subsequent patent applications in any jurisdiction claiming the same priority date and directed to the same subject matter as the patent application listed, and any divisionals, continuations, continuation-in-part applications, and continued prosecution applications (and their relevant international equivalents) of the patent applications listed, and the resulting patents, and
any patents resulting from reissues, reexaminations (and their relevant international equivalents) of the patents described in (a) and (b) above.
International Patent applications filed by MPG entitled 'Small expressed RNA molecules (MicroRNA molecules)'
Licensed Service shall mean any service (I) that, or the performance or sale of which, absent the license granted hereunder, would infringe one or more Pending Claims or Valid Claims of the MPG Patent Rights, or (ii) which, when performed, uses a Licensed Process or a Licensed Product.
(a) Companys internal and collaborative research and development purposes, and
(b) Diagnostic Purposes, specifically excluding any sale and use of Licensed Products, or performance and sale of Licensed Services, for Research Purposes or for Therapeutic Purposes.
IPSCIO Record ID: 245927
Patent Rights shall mean: (a) the United States and international patents listed.
US Patent Application #10/108,195 titled Methods and Products related to FGF Dimerization
(b) the United States and international patent applications and/or provisional applications listed and the resulting patents; (c) any patent applications resulting from the provisional applications listed, and any divisionals, continuations, continuation-in-part applications, and continued prosecution applications (and their relevant international equivalents) of the patent applications listed and of such patent applications that result from the provisional applications listed, to the extent the claims are directed to subject matter specifically described in the patent applications listed, and the resulting patents; (d) any patents resulting from reissues, reexaminations, or extensions (and their relevant international equivalents) of the patents described in (a), (b), and (c) above; and (e) international (non-United States) patent applications and provisional applications filed after the effective date and the relevant international equivalents to divisionals, continuations, continuation-in-part applications and continued prosecution applications of the patent applications to the extent the claims are directed to subject matter specifically described in the patents or patent applications referred to in (a), (b), (c), and (d) above, and the resulting patents.
Licensed Process shall mean any process that, absent the license granted hereunder, would infringe one or more valid claims of the Patent Rights or which uses a Licensed Product.
United States Patents and Applications
M.I.T. Case No. 9265
'A Novel Fibroblast Growth Factor Dimer'
International (non-U.S.) Patents and Applications
M.I.T. Case No. 9265
'A Novel Fibroblast Growth Factor Dimer'
WO Patent Application Serial No US02/09517, Filed on March 27, 2002
Entitled: METHODS AND PRODUCTS RELATED TO FGF DIMERIZATION
patents pertain to a novel molecule for treatment of neurological disorders, including stroke.
IPSCIO Record ID: 211894
In order to establish co-exclusivity, Licensor shall not grant, during the Term, more than three other co-exclusive licenses to the Licensed Patent Rights in the Field with the scope of Other Diagnostic Licenses, or the Other Diagnostic Licensees.
Licensee shall have the right to grant sublicenses.
The Platform Technologies shall mean any technology for qualitative and/or quantitative detection or quantification of nucleic acids and genotyping used in the performance of a Licensed Service or offered as part of a Licensed Product, including, without limitation, RNA extraction and/or PCR technologies, including, without limitation, realtime based, microarray technologies, or any current or future technology providing substantially similar results.by any means.
Patents filed are for Small expressed RNA molecules (MicroRNA molecules).
Analyte Specific Reagents or ASRs shall mean antibodies, both polyclonal and monoclonal, specific receptor proteins, ligands, nucleic acid sequences, and similar reagents which, through specific binding or chemical reaction with substances in a specimen, are intended for use in a diagnostic application for identification and quantification of an individual chemical substance or ligand in biological specimens. ASRs that otherwise fall within this definition shall not fall within this definition when they are sold to in vitro diagnostic manufacturers for the purpose of manufacturing in vitro diagnostic products, or organizations that use the reagents to make tests for purposes other than providing diagnostic information to patients and practitioners, e.g., forensic, academic, research, and other non-clinical laboratories.
The licensed microRNAs sequences will be added to Licensee microRNA database, providing the company with additional biomarker candidates for its diagnostic development programs. Under the terms of the agreement, Licensee will be able to use these microRNAs to advance multiple research and development programs targeting new microRNA-based diagnostic tools for a variety of diseases.
IPSCIO Record ID: 223124
RNA interference, or RNAi, is a naturally occurring mechanism within cells for selectively silencing specific genes, an ability that could become the basis for a whole new class of therapeutic products. The discovery of RNAi has been heralded by many as a major breakthrough, and the journal Science named RNAi the top scientific achievement of 2002 as well as one of the top ten scientific advances of 2003. Because many diseases are caused by the inappropriate activity of specific genes, the ability to silence such genes selectively through RNAi could provide a means to treat a wide range of human diseases.
Licensed Patents means the U.S. Patent Applications listed below and any divisions, continuations, reissues, reexamines, extensions and continuations-in-part applications thereof and any patents issuing thereto; and any and all foreign patents, foreign applications, extensions and supplemental protection certificates or patent applications corresponding thereto having the Principal Investigator as an inventor and claiming the same priority date as a parent application.
Serial No. Type Tite Date Filed Status
PCT/US01/08435 PCT Methods and Compositions for RNA Interference 3/16/01 Published
09/858,862 CIP Methods and Compositions for RNA Interference 5/16/01 Pending
09/866,551 CIP Methods and Compositions for RNA Interference 5/24/01 Pending
10/055,797 CIP Methods and Compositions for RNA Interference 1/22/02 Pending
Licensed Product means any product, including but not limited to any lyophilized liquid, sustained release or aerosolized formulation or other formulation, or process for which Licensee, or its Affiliate has received FDA Approval and/or Regulatory Approval, which is made through the use of Licensor Know-How or falls within the scope of a Valid Claim of a Licensed Patent.